Chandan Healthcare (CHANDAN) H1 FY27 Results: Centres Up 2.9x
Chandan Healthcare Limited (NSE Emerge: CHANDAN) - Share price: ₹235 (18 Nov 2026, screener.in) - Market cap: ₹574 crore (18 Nov 2026, screener.in) - P/E: 19.2x (listed diagnostics peers: median 37.8x) - ROCE: 22.8% - 52-week high / low: ₹352 / ₹185
Chandan Healthcare (CHANDAN) H1 FY27 results: franchise centres grew from 235 in March 2026 to 685 in September 2026 as the margin rose.
The company shared these numbers in its H1 FY27 investor presentation (dated 14 Nov 2026). Management now wants 1,000 franchise centres by March 2027 and 3,000 two years after that.
This article reads that presentation and asks one question: is the growth visible, and is it paid for in a way that holds up?
What Chandan Healthcare (CHANDAN) does
Chandan Healthcare traces its first diagnostic centre to Lucknow in 1991. The company was incorporated in 2003 and listed on NSE Emerge on 17 February 2025. It is an SME-platform stock, so it trades with lower liquidity than a mainboard stock.
It runs pathology and radiology (CT and MRI) labs and centres. The presentation lists:
- 23 Comprehensive Diagnostic Centres, 18 Diagnostic Centres and 25 standalone laboratories - 2 Central Reference Laboratories, at Lucknow and Haldwani - 16 MRI machines and 20 CT machines - Operations in 15 states, with 40,000+ referring doctors - 500+ franchise collection centres at the time the slide was made (685 by 30 September 2026)
Dr. Amar Singh is Chairman and Managing Director. He is a promoter, holds an MBBS and has been with the company since it began. Promoters and promoter group hold 48.42% (30 Sep 2026).
Chandan Healthcare franchise growth: 410 centres in one quarter
A franchise centre is a small collection point. A local operator takes the patient's sample. The sample goes to the nearest Chandan lab. The report goes out online. According to the presentation, the franchise partner puts in about ₹1 lakh for a computer, a printer and premises fit-out. Chandan puts in no capital.
Date Franchise centres Status --------- 31 Mar 2026 235 Achieved 30 Jun 2026 264 Achieved 30 Sep 2026 685 Achieved (410 added in Q2 FY27) End FY27 (Mar 2027) 1,000 Company target Two years after FY27 3,000 Company target
Why this matters: more samples flow into labs that already exist. Management says extra samples raise lab use without much extra cost at the lab. That is the operating leverage behind the margin story below.
Chandan Healthcare H1 FY27 margin expansion: from 31.18% to 36.95%
All figures below are standalone, in ₹ crore.
Period Revenue EBITDA EBITDA margin ------------ H1 FY26 75.53 24.21 31.18% H1 FY27 106.61 40.31 36.95% Q2 FY26 39.95 14.29 34.85% Q2 FY27 57.94 22.12 37.26%
- H1 revenue grew 41.16% and EBITDA grew 66.52%. The margin rose 576 basis points. - Q2 revenue grew 45.04% and EBITDA grew 54.79%. The margin rose 241 basis points. - Q2 margin was also higher than Q1 FY27 (36.57%). - Management gives two reasons: the exit from the low-margin pharmacy business, and more volume through existing hubs.
Management also gives centre-level economics: mature Comprehensive Diagnostic Centres earn 45-50% EBITDA, Diagnostic Centres 40-45%, and a standalone lab can turn EBITDA-positive in 3-4 months. These are the company's own claims.
Chandan Healthcare pharmacy exit and the profit headline
In August 2026 the company sold its 53.56% stake in Chandan Pharmacy Limited for ₹16.77 crore. More than 70% of the pharmacy's revenue was low-margin supply to a group company. The sale raised a one-time gain of ₹10.23 crore after tax (₹12.03 crore before tax).
That gain inflates the profit headline. Read the table with care.
Standalone, ₹ crore Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 --------------- Profit before exceptional item 7.88 12.91 11.39 22.87 One-time pharmacy gain (after tax) - 10.23 - 10.23 Reported PAT 5.74 18.61 7.11 25.37
- Reported PAT grew 256.72% in H1. That figure includes the one-time gain. - Profit before the exceptional item grew 100.76% in H1 and 63.88% in Q2. This is the better guide to the core business. - Without the gain, H1 FY27 PAT is about ₹15.14 crore, which is about 13.9% of total income (₹109.12 crore).
Chandan Healthcare three revenue engines
Segment Share of Q2 FY27 revenue Growth year on year --------- B2B (hospitals, insurers, corporates) 36.7% +106.5% B2C (retail patients) 34.5% +23.8% B2G (government projects) 28.8% +17.2%
- B2B runs on 230+ institutional clients. Chandan is the exclusive diagnostics partner of Jeena Sikho Lifecare Limited for 5 years. About 80% of Jeena Sikho locations are live, and monthly revenue from them has crossed ₹1.50 crore. Jeena Sikho also subscribed to 18,00,000 of the 44,50,000 warrants in Chandan's October 2025 preferential issue. - B2G has 10-year public-private partnerships (PPPs). Punjab has 12 sites (11 handed over), Assam has the Guwahati railway hospital project, and Haryana's Rohtak site is awaiting handover. Uttarakhand has been running since 2021. Management wants B2G to stay at about 40% of the mix or lower. - B2C includes walk-in patients, home collection, and the Chandan 24x7 app (3 lakh+ users).
Chandan Healthcare annual numbers, and a warning from FY26
Standalone figures from the presentation, ₹ crore.
FY24 FY25 FY26 ------------ Total income 100.87 130.47 160.86 EBITDA 26.44 38.16 54.01 Finance costs 2.11 3.57 11.86 Depreciation 3.36 6.42 13.78 PAT 16.02 20.78 19.82 Fixed assets 43.53 75.59 144.22 Trade receivables 21.86 31.31 44.19 Borrowings (long and short term) 29.08 33.20 38.63
- FY26 EBITDA rose 41.5%, but PAT slipped from 20.78 to 19.82. Higher interest and depreciation, from a big jump in fixed assets, ate the gain. - Debt-to-equity was 0.24 in FY26, as given in the deck. - Trade receivables rose to ₹44.19 crore, about 28% of FY26 revenue. By my own calculation that is about 103 days of sales, up from about 80 days in FY24. Receivables are money customers still owe the company. - The deck's cash flow statement was not part of the extract used here, so this article does not judge how much profit turned into cash.
How the Chandan Healthcare valuation compares
Peer data is from the screener.in peer table, 18 Nov 2026.
Company Price (₹) P/E Market cap (₹ crore) ROCE --------------- Chandan Healthcare 234.75 19.25 574 22.79% Krsnaa Diagnostics 514.55 16.54 1,669 12.71% Suraksha Diagnostic 351.60 43.79 1,831 17.29% Thyrocare 516.35 46.95 8,229 35.38% Metropolis 569.50 51.20 11,819 17.81% Dr Lal PathLabs 1,985.30 55.02 33,323 28.00% Vijaya Diagnostic 1,473.45 74.51 15,176 20.53%
Chandan trades at about half the peer median P/E (37.8x). It is far smaller than most of these companies. The reported profit behind the P/E includes the one-time pharmacy gain, so the P/E on core profit would be higher. Treat the gap with care.
Diagnostics market size for Chandan Healthcare
The presentation gives these industry figures (the deck does not name its source for them):
- Indian diagnostics market: ₹860-870 billion in FY24, projected ₹1,275-1,375 billion by FY28, growing 10-12% a year. - Organised chains hold 20-24% of the market. About three-quarters is still unorganised. - Pathology is about 56% of the market and radiology about 44%. Radiology is expected to grow 11-13% a year. - Tier-2 and tier-3 demand grows about 25% a year against about 10% in metros. These markets are about 40% of industry revenue.
What Chandan Healthcare management plans
These are the company's own forward-looking statements, not promises. Management gave no revenue or profit guidance.
- 1,000 franchise centres by end FY27 (from 685), and 3,000+ across 17 states two years later. - Eight Comprehensive Diagnostic Centres are nearing completion. - More than six Diagnostic Centres with lab and radiology are under development. - Four to five Comprehensive Diagnostic Centres and ten to twelve standalone labs are planned this year. - A genome sequencing lab at Jankipuram, Lucknow, and two PET-CT centres at Kanpur and Gorakhpur. - The Punjab radiology centres and the Guwahati radiology centre are to be commissioned. - Remaining capital spend of about ₹10 crore, from internal accruals, with the expansion programme targeted before December 2026. - Medium term: 40 Comprehensive Diagnostic Centres, 50 Diagnostic Centres, 100+ Chandan Medical Centres, and a lab in every district of Uttar Pradesh and Uttarakhand ("One District, One Lab") within two years. - Pharmacy sale proceeds go to new diagnostic centres. Growth of B2G and the Jeena Sikho business is a priority for H2 FY27. - Two units of Ansh Diagnostics & Health Care in Ghaziabad were acquired under an agreement dated 25 Sep 2026. They add pathology and CT/MRI.
Chandan Healthcare risks
- Uttar Pradesh concentration: about 80% of franchise centres are in Uttar Pradesh. Copying the model in new states is not proven. - Quality at speed: 410 centres were added in one quarter. Franchise partners are harder to control than owned centres. - Rising interest cost: finance costs rose 46% in H1 FY27 (₹5.93 crore to ₹8.65 crore). - Profit comparison: H1 FY27 reported profit includes a one-time gain. Future quarters will have no such gain. - Government contracts: the Haryana site was still waiting for handover in the presentation. Delays hurt B2G growth. - Small, SME-listed stock: low trading volume can make buying and selling hard.
The key point Chandan's growth is visible in its own numbers: 685 franchise centres and a 36.95% EBITDA margin. The reported profit jump is not the proof, because it includes a one-time ₹10.23 crore gain. Look at profit before that gain.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://nsearchives.nseindia.in/corporate/CHANDAN17112026191653NSE-H1FY27InvestorPresentationv2.pdf